GLP-1 receptor agonists have revolutionized the treatment of type 2 diabetes and obesity, with blockbuster drugs like semaglutide and tirzepatide transforming patient care. The GLP-1 Receptor Agonist Market is projected to reach USD 7.38 billion in 2026 and is expected to continue growing at a CAGR of 13.31%, reaching USD 15.70 billion by 2032[reference:110].
GLP-1 (glucagon-like peptide-1) is an incretin hormone that stimulates insulin secretion, inhibits glucagon release, and promotes satiety. Native GLP-1 has a very short half-life (approximately 2 minutes) due to rapid degradation by DPP-4. GLP-1 receptor agonists are engineered to resist degradation, providing sustained activity with once-daily or once-weekly dosing.
Current GLP-1 receptor agonists include semaglutide (Novo Nordisk), liraglutide (Novo Nordisk), and tirzepatide (Eli Lilly). These drugs have demonstrated remarkable efficacy in lowering HbA1c and promoting weight loss. Tirzepatide, a dual GLP-1/GIP agonist, has shown even greater efficacy than selective GLP-1 agonists, establishing the potential of multi-target approaches.
Beyond diabetes and obesity, GLP-1 receptor agonists are being investigated for cardiovascular disease, chronic kidney disease, non-alcoholic steatohepatitis (NASH), and neurodegenerative disorders. The cardioprotective effects of GLP-1 agonists have been established in large clinical trials, and ongoing studies are exploring additional indications.
For researchers, high-quality GLP-1 receptor agonist peptides are essential for in vitro and in vivo studies. These peptides are used to study receptor signaling, investigate mechanisms of action, and develop next-generation agonists. At PeptideHub, we provide a comprehensive range of GLP-1 receptor agonist peptides for research applications, with high purity and full analytical documentation.